Lenskart IPO Day 3: Check Subscription Status & Key Highlights
The ?7,278.02 crore initial public offering (IPO) of Lenskart enters its final day of subscription today, 4 November, 2025. Till the end of day 2, the IPO was subscribed to 2.01 times.?
Lenskart IPO: Issue Details
- Issue Size: Lenskart IPO is a book-building issue of ?7,278.02 crores, consisting of a fresh issue of ?2,150.00 crores and an offer for sale of ?5,128.02 crores.
- Price Band: The price band is set between ?382 and ?402 per share.
- Book-running lead manager: Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Avendus Capital Private Limited, Citigroup Global Markets India Private Limited, Axis Capital Limited, and Intensive Fiscal Services Private Limited
- Registrar: Bigshare Services Private Limited
- Listing: The shares are proposed to be listed on the NSE and the BSE on November 10.?
Lenskart IPO Day 3: Subscription Details
[4-November-2025 19:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
40.35 |
|
Non-Institutional Investors |
18.23 |
|
Retail Individual Investors (RIIs) |
7.54 |
|
Employees |
4.96 |
|
Total |
28.26 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be distributed towards?
- Brand marketing and promotion activities?
- Invest in cloud and tech infrastructure
- Fund capital expenditure towards the set-up of new CoCo stores in India
- Fund capital expenditure towards lease/rent/licence agreement-related payments for CoCo stores
- General corporate purposes?
- Unidentified inorganic acquisitions?
Lenskart Business Overview?
Lenskart is one of India’s leading omni-channel eyewear retailers who’s engaged in designing, manufacturing, branding and retailing eyewear products. The company is India’s largest and one of Asia’s two largest organised retailers of prescription eyeglasses by B2C sales volume in FY2025. (Source: Redseer Report)
Their product portfolio comprises of prescription eyeglasses, sunglasses, and other products such as contact lenses and eyewear accessories.?
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.?
To read the RA disclaimer, please click here
?